[go: up one dir, main page]

SG50585A1 - Glycoalkaloids - Google Patents

Glycoalkaloids

Info

Publication number
SG50585A1
SG50585A1 SG1996005588A SG1996005588A SG50585A1 SG 50585 A1 SG50585 A1 SG 50585A1 SG 1996005588 A SG1996005588 A SG 1996005588A SG 1996005588 A SG1996005588 A SG 1996005588A SG 50585 A1 SG50585 A1 SG 50585A1
Authority
SG
Singapore
Prior art keywords
cells
abnormal
cellular
removal
normal
Prior art date
Application number
SG1996005588A
Inventor
Bill Elliot Cham
Brian Daunter
Original Assignee
Cura Nominees Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cura Nominees Pty Ltd filed Critical Cura Nominees Pty Ltd
Publication of SG50585A1 publication Critical patent/SG50585A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0052—Nitrogen only at position 16(17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/14—Topical contraceptives and spermacides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

The invention is directed to the control of cellular autophagy, cellular agglutination and the immobilization of motile cells. Such control is useful in, for example, the treatment of cancer, contraception, termination of pregnancy, removal of pathogenic organisms and removal of any abnormal cellular growth (malignant or otherwise); as a diagnostic and analytical tool whereby cell structure can be studied and testing could be undertaken for the presence (and subsequent analysis) of pathogenic and non-pathogenic organisms; and in the manufacture of biochemicals whereby certain cells must be destroyed or otherwise contained. From surface analysis of normal and abnormal cells, specific receptors on abnormal cells which are either not present on normal cells or are only present in significantly reduced numbers can be identified. Alkaloids and other pharmaceutically acceptable compounds are preferentially recognized by the abnormal cells, and which bind thereto and subsequently destroy.
SG1996005588A 1990-01-18 1991-01-18 Glycoalkaloids SG50585A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ824390 1990-01-18

Publications (1)

Publication Number Publication Date
SG50585A1 true SG50585A1 (en) 1998-07-20

Family

ID=3774458

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005588A SG50585A1 (en) 1990-01-18 1991-01-18 Glycoalkaloids

Country Status (11)

Country Link
US (1) US5958770A (en)
EP (1) EP0515386B1 (en)
JP (1) JP3168542B2 (en)
KR (1) KR100213805B1 (en)
AT (1) ATE188036T1 (en)
AU (1) AU654474B2 (en)
BR (1) BR9105952A (en)
CA (1) CA2073855C (en)
DE (1) DE69131861T2 (en)
SG (1) SG50585A1 (en)
WO (1) WO1991010743A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004556A1 (en) * 1992-08-21 1994-03-03 New York University Aminofurostenes, compositions, and methods of use
GB9618119D0 (en) 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
HUP0103654A2 (en) * 1998-03-26 2002-02-28 Phytopharm Plc. Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US6867216B1 (en) 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
JP5067986B2 (en) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン Use of steroidal alkaloid derivatives as inhibitors of the hedgehog signaling pathway
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6344050B1 (en) 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
AU2005201269C1 (en) * 1999-01-13 2008-09-04 Curis, Inc. Regulators of the PCT or smoothened pathway, compositions and uses related thereto
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPP968699A0 (en) * 1999-04-09 1999-05-06 Cura Nominees Pty Ltd Therapeutic compositions and method for their preparation
TW471968B (en) * 1999-08-25 2002-01-11 Committee On Chinese Medicine Solamargine pharmaceutical composition for killing cancer cells
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU781524B2 (en) 1999-10-13 2005-05-26 Johns Hopkins University School Of Medicine, The Regulators of the hedgehog pathway, compositions and uses related thereto
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
KR20030045671A (en) 2000-04-28 2003-06-11 인플라자임 파마슈티칼즈 리미티드 3-Nitrogen-6,7-dioxygen steroids and uses related thereto
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
ATE400580T1 (en) * 2001-08-21 2008-07-15 Glycomed Sciences Ltd CHEMICAL SYNTHESIS OF SOLAMARGINE
US7479290B2 (en) 2001-09-28 2009-01-20 Glycomed Sciences Limited Solvent extraction process
WO2003030884A2 (en) * 2001-10-09 2003-04-17 Glycomed Sciences Limited Use of solasonine for the treatment of skin tumors
WO2003030915A1 (en) * 2001-10-09 2003-04-17 Glycomed Sciences Limited Use of solamargine for treating skin tumors
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
KR101130212B1 (en) * 2002-03-27 2012-04-13 파이토팜 피엘씨 Theraputic methods and uses of SAPOGENIN and their derivatives
US6984725B2 (en) * 2002-06-28 2006-01-10 Solbec Pharmaceuticals Ltd. Method for the separation of triglycoalkaloids
AUPS329002A0 (en) * 2002-07-01 2002-07-18 Solbec Pharmaceuticals Limited Glycoalkaloid compositions and various uses thereof
AU2003900194A0 (en) * 2003-01-15 2003-01-30 Solbec Pharmaceuticals Limited Methods of modulating il-6
TWI300352B (en) * 2003-06-05 2008-09-01 G & E Herbal Biotechnology Co Ltd Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract
CN1329038C (en) * 2003-06-20 2007-08-01 德英生物科技股份有限公司 Water-soluble extract of nightshade plant, its preparation method and its pharmaceutical composition
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
AU2006247244B2 (en) * 2005-05-17 2012-05-17 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
US20070149491A1 (en) * 2005-05-17 2007-06-28 Findeis Mark A Compounds useful for treating neurodegenerative disorders
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
WO2008130449A2 (en) * 2006-11-20 2008-10-30 Satori Pharmaceuticals, Inc. Modulators of amyloid-beta production
CA2670284C (en) * 2006-11-20 2013-03-26 Satori Pharmaceuticals, Inc. Synthesis of compounds useful as modulators of amyloid-beta production
EP2817340B1 (en) 2012-02-23 2020-12-09 Daiichi Sankyo Europe GmbH Her3 inhibitor for modulating radiosensitivity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR943800A (en) * 1946-12-31 1949-03-17 Improvements to cinematographic projectors using reduced format films
DE1804331A1 (en) * 1967-10-23 1969-05-22 Erba Carlo Spa Substd salicylanilide cpds anthelmintics
DE1900060A1 (en) * 1969-01-02 1970-08-13 Lentia Gmbh Opening of ring f in delta 22,23 solanidane - alkaloids (i) to give new androstane
GB1380253A (en) * 1971-01-21 1975-01-08 Inverni Della Beffa Spa Prosapogenins
DE2519261C3 (en) * 1975-04-30 1979-03-01 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Process for obtaining the main sapogenin contained in the roots and rhizomes of Helleborus species
NZ193564A (en) * 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
US4937182A (en) * 1985-12-19 1990-06-26 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
GB2192185B (en) * 1986-07-03 1991-01-16 Genetic Systems Corp Monoclonal antibodies to pseudomonas aeruginosa flagella
US5227160A (en) * 1988-07-15 1993-07-13 The Biomembrane Institute Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen
US5766632A (en) * 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception

Also Published As

Publication number Publication date
EP0515386B1 (en) 1999-12-22
US5958770A (en) 1999-09-28
BR9105952A (en) 1992-11-17
EP0515386A4 (en) 1993-10-27
EP0515386A1 (en) 1992-12-02
JPH05503847A (en) 1993-06-24
KR927003842A (en) 1992-12-18
JP3168542B2 (en) 2001-05-21
KR100213805B1 (en) 1999-08-02
DE69131861D1 (en) 2000-01-27
CA2073855C (en) 2007-04-24
CA2073855A1 (en) 1991-07-19
AU654474B2 (en) 1994-11-10
DE69131861T2 (en) 2000-05-18
WO1991010743A1 (en) 1991-07-25
ATE188036T1 (en) 2000-01-15
AU7159491A (en) 1991-08-05

Similar Documents

Publication Publication Date Title
KR100213805B1 (en) Glycoalkaloids
ATE215992T1 (en) ISOLATION OF FETAL ERYTHROCYTES
MX9707732A (en) Tricyclic compounds useful in the treatment of cell proliferative disorders.
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
AU2332288A (en) Compounds having antiprogestational and anti-estrogenic activities for induction of labor and for termination of pregnancy, as well as for the treatment of gynaecological disorders
AU2204795A (en) Method for processing mycobacteria
AU541099B2 (en) Detection of occult human blood
EP0554383A4 (en)
TR199802572T2 (en) Scanning methods for detecting compounds suitable for adjusting body weight.
CA2048619A1 (en) Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat lipopolysaccharide associated gram negative infections
AU4725796A (en) Preparation and use of a specific gaba-A alpha 5 receptor ligand for treatment of Alzheimer's disease
CA2224003A1 (en) Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
IT8719331A0 (en) CHUCK FOR FIXING CELL FOR BLOOD CENTRIFUGATION, AND SIMILAR.
AU555699B2 (en) Pp13 protein from placenta
CA2045552A1 (en) Cancer related haptoglobin
EG17029A (en) Process for the preparation antiulcer 2-guamidina-4-(2-substituted)amino-4-imidazolyl)thiazoles
ES2180769T3 (en) INHIBITION OF THE RELEASE OF AMILINA.
AU4632689A (en) Structural and enzymatic assays on glycocompounds, their use in the diagnosis of cancer, kits for use in the assays and a device for taking a sample of secretion via a body opening
AU7913887A (en) Method for the removal of undesired cells from human lymphocyte populations, application of the method in monoclonal antibody production and kit therefor
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
AU2087495A (en) Means for treating autoimmune diseases and a method for the treatment thereof
CA2078861A1 (en) Total gonadotropal alpha peptide chain assay
ES2059539T3 (en) METHOD FOR THE PREVENTION OF GRAFT DISEASE AGAINST THE GUEST.
RO103682B1 (en) Isolation method of human ceruloplasmin
SU1167197A1 (en) Pseudomonas diminuta inmi kc-7 strain used for removing 3,4-dichloraniline from waste water